Poultry Vaccines Global Market Opportunities and Strategies to 2033

This report describes and explains the poultry vaccines market and covers 2018-2023, termed the historic period, and 2023-2028, 2033F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global poultry vaccines market reached a value of nearly $2.01 billion in 2023, having grown at a compound annual growth rate (CAGR) of 4.60% since 2018. The market is expected to grow from $2.01 billion in 2023 to $2.85 billion in 2028 at a rate of 7.16%. The market is then expected to grow at a CAGR of 7.73% from 2028 and reach $4.14 billion in 2033.

Growth in the historic period resulted from rise in consumption of protein and meat, increased disease prevalence in poultry, increase in global trade in poultry products, strong economic growth in emerging markets. Factors that negatively affected growth in the historic period were rising awareness of animal cruelty.

Going forward, rise in production of meat and eggs, growing occurrence of zoonotic diseases, government initiatives or schemes for testing vaccines for poultry, emergence of new poultry diseases will drive the market growth. Factor that could hinder the growth of the poultry vaccines market in the future include shortages of raw materials or logistical challenges.

The poultry vaccines market is segmented by disease type into infectious bronchitis, avian influenza, Newcastle disease, Marek’s disease and other diseases. The infectious bronchitis market was the largest segment of the poultry vaccines market segmented by disease type, accounting for 26.3% or $531.09 million of the total in 2023. Going forward, the avian influenza segment is expected to be the fastest growing segment in the poultry vaccines market segmented by disease type, at a CAGR of 7.98% during 2023-2028.

The poultry vaccines market is segmented by vaccines type into live attenuated vaccines, inactivated vaccines and other vaccines types. The live attenuated vaccines market was the largest segment of the poultry vaccines market segmented by vaccines type, accounting for 64.7% or $1.3 billion of the total in 2023. Going forward, the other vaccines types segment is expected to be the fastest growing segment in the poultry vaccines market segmented by vaccines type, at a CAGR of 8.33% during 2023-2028.

The poultry vaccines market is segmented by application into broiler, layer and breeder. The breeder market was the largest segment of the poultry vaccines market segmented by application, accounting for 54% or $1.09 billion of the total in 2023. Going forward, the broiler segment is expected to be the fastest growing segment in the poultry vaccines market segmented by application, at a CAGR of 7.61% during 2023-2028.

The poultry vaccines market is segmented by dosage form into liquid vaccine and freeze dried vaccine. The liquid vaccine market was the largest segment of the poultry vaccines market segmented by dosage form, accounting for 67.5% or $1.36 billion of the total in 2023. Going forward, the freeze dried vaccine segment is expected to be the fastest growing segment in the poultry vaccines market segmented by dosage form, at a CAGR of 7.66% during 2023-2028.

North America was the largest region in the poultry vaccines market, accounting for 29.9% or $604.3 million of the total in 2023. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the poultry vaccines market will be Asia Pacific and Middle East where growth will be at CAGRs of 9.6% and 6.7% respectively. These will be followed by Western Europe and North America where the markets are expected to grow at CAGRs of 6.4% and 6.2% respectively.

The global poultry vaccines market is highly concentrated, with large players operating in the market. The top ten competitors in the market made up to 60.9% of the total market in 2022. The market concentration can be attributed to the presence of large players in different geographies. Boehringer Ingelheim International GmbH was the largest competitor with a 18.4% share of the market, followed by Elanco Animal Health Incorporated with 13.2%, Merck & Co. Inc. with 8.7%, Zoetis Inc. with 7.5%, Ceva Santé Animale with 5.2%, HIPRA, S.A., with 3%, Tianjin Ringpu Bio-Technology Co., Ltd. (Ringpu Biology) with 1.7%, Vaxxinova International BV with 1.3%, Phibro Animal Health Corporation with 1.1% and Dechra Pharmaceuticals PLC with 0.8%.

The top opportunities in the poultry vaccines market segmented by disease type will arise in the infectious bronchitis segment, which will gain $194.7 million of global annual sales by 2028. The top opportunities in the poultry vaccines market segmented by vaccines type will arise in the live attenuated vaccine segment, which will gain $510.8 million of global annual sales by 2028. The top opportunities in the poultry vaccines market segmented by application will arise in the breeder segment, which will gain $452.7 million of global annual sales by 2028. The top opportunities in the poultry vaccines market segmented by dosage form will arise in the liquid vaccine segment, which will gain $541.1 million of global annual sales by 2028. The poultry vaccines market size will gain the most in the USA at $193.8 million.

Market-trend-based strategies for the poultry vaccines market include focusing on developing new, innovative products to protect against a variety of poultry diseases, developing low-pathogenic avian influenza (LPAI) vaccines to enhance their offerings, focusing on strategic collaborations to strengthen their product portfolio and expand their geographic presence, focusing on new investments in research and developments in poultry vaccines.

Player-adopted strategies in the poultry vaccines market include focus on strengthening business capabilities through new product launches, focus on strengthening business operations through strategic partnerships.

To take advantage of the opportunities, the analyst recommends the poultry vaccines companies to focus on innovative product development, focus on low-pathogenic avian influenza (LPAI) vaccines, focus on strategic investments, focus on technological advancements for enhanced vaccination solutions, focus on infectious bronchitis and new castle disease segments, focus on live attenuated vaccines segment, expand in emerging markets, continue to focus on developed markets, focus on strategic collaborations for enhanced vaccine portfolio, provide competitively priced offerings, participate in trade shows and events, continue to use B2B promotions, focus on government-supported vaccine testing and focus on targeting poultry producers.